ABTABT
US • —
$90.74
P/E
25.27
PEG
—
FCF Yield
—
Rev Growth YoY
+6.6% YoY
Gross Margin
56.5%
Health Score
7/10
D/E Ratio
0.25
Confidence
MEDIUM
Business Snapshot
Abbott Laboratories (ABT) is a diversified healthcare company operating across medical devices, diagnostics, nutrition, and established pharmaceuticals. Its primary revenue-generating segments include diabetes care (FreeStyle Libre continuous glucose monitoring system), cardiovascular devices, and diagnostic testing solutions. The company is a dominant player in the global diagnostics and medical device markets, leveraging decades of brand trust and a broad product portfolio. As a large-cap company with strong brand recognition, Abbott is defined by its diversified business model across relatively defensive healthcare sub-sectors, providing revenue stability. A key characteristic is its regulatory and innovation moat in continuous glucose monitoring, a high-growth market where it holds a leading position.
Financial Health
Abbott's profitability is supported by a gross margin of 56.5%, though net margin stands at a comparatively thinner 13.9%. The balance sheet is in strong shape, with a conservative debt-to-equity ratio of 0.25x and a current ratio of 1.58x, indicating a healthy ability to meet short-term obligations and low financial leverage...
Risk Assessment
- EARNINGS QUALITY — The company beat earnings estimates in 0 of the last 4 quarters, indicating persistent guidance shortfalls and potential forecasting opacity.
- EARNINGS DECLINE — Earnings growth of -53.6% YoY stands in stark contrast to modest revenue growth of 6.6%, signalling significant operational or cost-side headwinds.
- VALUATION — The P/E ratio of 25.27x trades at a premium to the sector average of 22x, with no clear growth catalyst to justify the higher multiple.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....
Abbott's profitability is supported by a gross margin of 56.5%, though net margin stands at a comparatively thinner 13.9%. The balance sheet is in strong shape, with a conservative debt-to-equity ratio of 0.25x and a current ratio of 1.58x, indicating a healthy ability to meet short-term obligations and low financial leverage. Free cash flow data is not available, making it difficult to fully assess cash generation and capital allocation flexibility. Overall, Abbott exhibits a low-risk balance sheet with moderate operating margins, suggesting it maintains the capacity for dividend payments and reinvestment in its core businesses, though a full cash flow picture remains absent.
- EARNINGS QUALITY — The company beat earnings estimates in 0 of the last 4 quarters, indicating persistent guidance shortfalls and potential forecasting opacity. - EARNINGS DECLINE — Earnings growth of -53.6% YoY stands in stark contrast to modest revenue growth of 6.6%, signalling significant operational or cost-side headwinds. - VALUATION — The P/E ratio of 25.27x trades at a premium to the sector average of 22x, with no clear growth catalyst to justify the higher multiple. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives